Brokerages Expect Kindred Biosciences Inc (KIN) Will Announce Earnings of -$0.42 Per Share
Brokerages forecast that Kindred Biosciences Inc (NASDAQ:KIN) will announce ($0.42) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Kindred Biosciences’ earnings, with estimates ranging from ($0.43) to ($0.40). Kindred Biosciences reported earnings of ($0.35) per share in the same quarter last year, which suggests a negative year over year growth rate of 20%. The firm is scheduled to announce its next earnings report on Thursday, March 7th.
On average, analysts expect that Kindred Biosciences will report full year earnings of ($1.59) per share for the current financial year, with EPS estimates ranging from ($1.65) to ($1.54). For the next year, analysts expect that the business will report earnings of ($1.44) per share, with EPS estimates ranging from ($1.46) to ($1.42). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Kindred Biosciences.
Kindred Biosciences (NASDAQ:KIN) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $0.64 million during the quarter.
Kindred Biosciences stock traded down $0.42 during trading on Friday, hitting $12.13. The stock had a trading volume of 1,169 shares, compared to its average volume of 122,367. Kindred Biosciences has a 1 year low of $7.45 and a 1 year high of $15.75. The company has a market cap of $425.61 million, a price-to-earnings ratio of -10.02 and a beta of 0.23.
In other Kindred Biosciences news, insider Richard Chin sold 40,000 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $13.28, for a total transaction of $531,200.00. Following the sale, the insider now owns 2,026,071 shares in the company, valued at $26,906,222.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Raymond Townsend sold 3,000 shares of the stock in a transaction on Wednesday, September 26th. The stock was sold at an average price of $13.32, for a total value of $39,960.00. Following the sale, the director now owns 27,813 shares in the company, valued at approximately $370,469.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 123,000 shares of company stock worth $1,689,560. 15.96% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the business. Metropolitan Life Insurance Co. NY bought a new position in shares of Kindred Biosciences in the second quarter worth $103,000. Tower Research Capital LLC TRC increased its holdings in shares of Kindred Biosciences by 764.3% in the second quarter. Tower Research Capital LLC TRC now owns 9,671 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 8,552 shares during the period. Paloma Partners Management Co bought a new position in shares of Kindred Biosciences in the second quarter worth $119,000. Meeder Asset Management Inc. increased its holdings in shares of Kindred Biosciences by 90.1% in the third quarter. Meeder Asset Management Inc. now owns 8,698 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 4,122 shares during the period. Finally, MetLife Investment Advisors LLC bought a new position in shares of Kindred Biosciences in the second quarter worth $146,000. Hedge funds and other institutional investors own 66.43% of the company’s stock.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc, a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
Featured Story: How Important is Technical Analysis of Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.